Despite the availability of different antipsychotics for the treatment of schizophrenia, in clinical practice it is somewhat of a struggle to identify an antipsychotic medication for individual patients that they are willing to adhere to. Brexpiprazole is a new molecular entity that is a dopamine receptor partial agonist that differs from aripiprazole in terms of greater potency at serotonin 5-HT1A receptors and less intrinsic activity at dopamine D2 receptors.1 Brexpiprazole received approval in the USA for the treatment of schizophrenia in July 2015......To read the full article, log in using your NHS OpenAthens details